SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around its position within the Bitcoin ecosystem and Rune revolution. Community members highlight the growing $DOG treasury and accumulation, with some anticipating potential listings on major exchanges. The focus remains on $DOG's role in onboarding new users to Bitcoin and its potential for significant growth.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy (SWEAT) is trending as community members highlight its move-to-earn concept, where users earn cryptocurrency by walking and staying active. Many see SWEAT as an undervalued project with long-term potential, incentivizing a healthy lifestyle while accumulating crypto. Others discuss the utility of SWEAT within its ecosystem, using it for staking, raffles, and gift cards.

English version Introducing SWFTCoin (SWFTC) $SWFTC: Powering SWFT Blockchain and AI Services (SWFTGPT)  SwftCoin ($SWFTC) is the native utility token driving SWFT Blockchain's AI-powered ecosystem, SWFTGPT, and the first ever AI token featured on Coinbase. SWFTGPT is also the first domain-specific LLM for crypto.  SwftCoin key features include: 50% Reduced Transaction Fees: Lower costs on all transactions. AI Service Payments: Use $SWFTC to access SWFTGPT. Tools include expert market analysis,  predictions, and intelligent trading solutions.  Membership Benefits: Unlock premium features and AI agent services within SWFTGPT. AI-Powered Swaps: Enable precise, fast cross-chain transactions and analytics. SWFT Blockchain combines AI innovation with blockchain infrastructure, simplifying crypto trading while enhancing functionality through $SWFTC.   Chinese version $SWFTC：驱动 SWFT Blockchain 和 AI 服务（SWFTGPT） SwftCoin ($SWFTC) 是 SWFT Blockchain 的原生实用代币，为其 AI 驱动的生态系统 SWFTGPT 提供支持，同时也是 Coinbase 上首个 AI 代币。SWFTGPT 也是首个专注于加密领域的特定领域大型语言模型 (LLM)。 SwftCoin 的主要功能包括： 1、50% 交易费减免：降低所有交易成本。 2、AI 服务支付：使用 $SWFTC 访问 SWFTGPT 工具，包括专家市场分析、预测以及智能交易解决方案。 3、会员权益：解锁 SWFTGPT 的高级功能和 AI 代理服务。 4、AI 驱动的闪兑：实现精准快速的跨链交易和数据分析。 SWFT Blockchain 将 AI 创新与区块链基础设施结合，通过 $SWFTC 简化加密交易，并提升其功能性。

SwftCoin

SwftCoin is trending as traders speculate about potential for significant gains, reminiscent of past rallies, given its small market cap and fully diluted supply. The community is actively discussing accumulation strategies and anticipating a breakout, while also referencing potential partnerships and platform updates. Some traders express concerns about promotional efforts and historical price action.

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

TENX is trending due to anticipation surrounding upcoming presentations and potential Phase 3 trial updates, particularly around their drug candidate TNX-103. The community is actively discussing the possibility of a short squeeze, spurred by mentions of high ownership and low float, with some drawing parallels to other high-flying stocks. Chatter also includes speculation around potential insider buying and strategic positioning by key investors.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

IDYA is trending due to positive Phase 2 data for its uveal melanoma treatment, darovasertib, which showed promising results in tumor shrinkage and eye preservation; the community is buzzing about its potential. Bullish sentiment is further fueled by analyst upgrades and a recent partnership, though an upcoming offering has introduced some caution. Despite some profit-taking, many view IDYA as undervalued with a strong pipeline and potential for significant growth in the oncology space.

Ethereum Classic

Ethereum Classic is trending as the crypto market experiences volatility, sparking discussions about potential decoupling from leading cryptocurrencies like Bitcoin and Ethereum. Community members are analyzing technical charts and expressing a mix of frustration and hope, while also considering ETC's historical performance and future potential relative to ETH. Many are weighing whether to hold, accumulate, or sell their positions amidst broader concerns about altcoin performance.

LendingClub Corp. engages in the operations of digital marketplace bank. It operates through the LendingClub Bank and LendingClub Corporation (Parent Only) segments. The LendingClub Bank segment involves the provision of full complement of financial products and solutions, loans, leases, and deposits. The LendingClub Corporation (Parent Only) segment includes the holding company legal entity. The company was founded by Renaud Laplanche and Soulaiman Htite in 2006 and is headquartered in San Francisco, CA.

LendingClub Corp

LendingClub is trending as investors assess its potential in light of recent analyst ratings and the upcoming earnings report. Community discussions revolve around the company's valuation compared to peers like SOFI and UPST, as well as its growth strategy and marketing efforts. Some are optimistic about future rate cuts and potential buybacks, while others express concerns about conservative management and the overall macro environment.

Peloton Interactive, Inc. provides an at-home fitness platform for live and on-demand indoor cycling classes. The firm pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its members. It operates through the Connected Fitness Products and Subscription segments. The Connected Fitness Products segment includes the sales of bikes, tread & related accessories. The Subscription segment refers to the monthly subscription and credits from live studio classes. The company was founded by John Foley, Graham Stanton, Thomas Cortese, Yony Feng, and Hisao Kushi in 2012 and is headquartered in New York, NY.

Peloton Interactive Inc - Ordinary Shares - Class A

Peloton Interactive Inc

Peloton is trending as the community discusses recent analyst upgrades and anticipation surrounding a potential AI integration and new hardware launch, despite some skepticism about the broader economic conditions impacting the stock; options activity indicates bullish sentiment with call sweeps at higher strike prices.

BlackLine, Inc. engages in providing a cloud-based software platform that automates and controls financial close and accounting processes. It operates through the United States and International geographical segments. The company was founded by Therese Tucker in May 2001 and is headquartered in Woodland Hills, CA.

BlackLine Inc

Recent reports suggest BlackLine ($BL) may have attracted takeover interest, specifically with rumors of Apollo Management building a stake, leading to community speculation about a potential acquisition. Despite some analyst downgrades and price target reductions, $BL is showing accumulation patterns, and investors are closely watching for a potential strategic move. Discussions also involve BlackLine's new AI and automation initiatives and their impact on financial operations.

Optimism is more than just a single blockchain – it's a growing network of chains called the Superchain, all built on the open-source OP Stack. While OP Mainnet was the first, many prominent chains now run on the Optimism’s OP Stack, including Base (by Coinbase), Unichain (by Uniswap), Ink (by Kraken), and World Chain (by Worldcoin). The OP Stack has become the leading framework for Ethereum Layer 2 chains, powering the majority of L2 activity today. Every OP Chain in the Superchain contributes back to the Optimism Collectiv and all chains follow a standardized revenue-sharing model: the greater of 2.5% of total chain revenue or 15% of onchain profit (defined as fees minus L1 gas costs) is paid back to the Optimism. By aligning economic incentives across many chains, Optimism transforms Ethereum scaling into a sustainable flywheel by delivering fast, low-cost transactions while reinvesting in the future of the ecosystem. OP holders participate in governance to shape protocol upgrades, funding decisions, and more.

Optimism Coin

Optimism (OP) is trending as traders react to recent buy signals and price fluctuations around the entry point, with the community closely watching for momentum shifts. Some view Starknet as a superior Layer 2 solution, while others express bullish sentiment toward OP amid overall optimism for alt season and potential tax benefits for Bitcoin. The ticker change from OP to SVRN may also be contributing to increased volume.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharmaceutical Stocks To Keep An Eye On - November 21st

Eli Lilly and Company, Pfizer, AbbVie, Gilead Sciences, Novo Nordisk A/S, Abbott Laboratories, and Regeneron Pharmaceuticals are the seven Pharmaceutical stocks to watch today, according to...

Prudential PLC Sells 27,809 Shares of Gilead Sciences, Inc. $GILD

Prudential PLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 12.5% during the second quarter, according to its most recent filing with the Securities and...

$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized...

Connor Clark & Lunn Investment Management Ltd. Has $673,000 Stock Position in Gilead Sciences, Inc. $GILD

Connor Clark & Lunn Investment Management Ltd. lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 97.1% during the 2nd quarter, according to its most recent...

Andrew Dickinson Sells 2,500 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, November 17th. The stock was sold at an...

Johanna Mercier Sells 28,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction dated Monday, November 17th. The shares were sold at an...

<ul class="summary-bullets"><li>The safety profile of the regimen was also found to be comparable to Biktarvy.&nbsp;</li><li>Merck now intends to present findings from the trial at a future science congress and submit applications to health authorities with this data.</li><li>The FDA is expected to decide on Merck’s application for the single-tablet regimen of Doravirine and Islatravir by April 28, 2026.&nbsp; &nbsp;</li></ul>Merck (MRK) on Thursday said that its investigational once-daily, oral, two-drug, single-tablet regimen of Doravirine and Islatravir was found to be non-inferior to Gilead Sciences’ FDA-approved Biktarvy in treating HIV patients who had not previously received treatment in a study.Merck <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.merck.com/news/merck-announces-positive-topline-results-from-the-pivotal-phase-3-trial-evaluating-investigational-once-daily-oral-two-drug-single-tablet-regimen-of-doravirine-islatravir-dor-isl-in-treatment-na/">said</a> that the combination achieved suppression of the HIV virus at week 48, similar to Biktarvy in the late-stage study. Further, the safety profile of the regimen was also found to be comparable to Biktarvy.<h2 class="st-heading-2">Steps Ahead</h2>Merck now intends to present findings from the trial at a future science congress and submit applications to health authorities with this data.The U.S. Food and Drug Administration has already accepted the company’s application for approval of the two-drug regimen for the treatment of an HIV infection in adults who are on an antiretroviral regimen. The FDA is now expected to decide on the application by April 28, 2026.In the two-drug regimen, Doravirine is already approved for the treatment of adults with HIV-1 in combination with other antiretrovirals under the brand name Pifeltro and as a component of a single-tablet regimen called Delstrigo. Islatravir, meanwhile, is an investigational drug from Merck under evaluation in multiple ongoing early and late-stage clinical trials in combination with other antiretrovirals for potential daily and once-weekly treatments for HIV-1.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRK fell from 'extremely bullish' to 'bullish' territory over the past 24 hours, while message volume fell from 'extremely high' to 'high' levels.<figure class="image"><img style="aspect-ratio:624/56;" src="data:image/png;base64,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" width="624" height="56" alt="MRK’s Sentiment Meter and Message Volume as of 1:10 p.m. ET on Nov. 19, 2025 | Source: Stocktwits"><figcaption>MRK’s Sentiment Meter and Message Volume as of 1:10 p.m. ET on Nov. 19, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/MRK">MRK stock</a> is down by 4.5% this year and by about 2% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/kzia-stock-soars-after-company-stage-iv-cancer-patients-shows-initial-complete-remission-on-its-drug-combination/cLPoQdMREBN">KZIA Stock Soars After Stage IV Cancer Patient Shows Initial Complete Remission On Its Drug Combination</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study

Merck said the combination achieved suppression of the HIV virus at week 48, similar to Biktarvy in the late-stage study.

Equity

Merck said the combination achieved suppression of the HIV virus at week 48, similar to Biktarvy in the late-stage study.


Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

GILD
Gilead Sciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GILD News

GILDGilead Sciences, Inc.